, VEGFR-2 inhibition, and anticancer activity of a 3-(hydrazonomethyl)naphthalene-2-ol derivative.

In agreement with the general features of VEGFR-2 inhibitors, a new naphthalene analog (compound ) has been designed and synthesized. The inhibitory potential of compound was indicated by the proper binding and the perfect energy of -21.10 kcal/mol compared to sorafenib (-21.22) in the molecular docking studies. Next, six MD simulation studies over 100 ns (RMSD, RMSF, SASA, RoG, hydrogen bonding, and distance between the center of mass) confirmed the accurate interaction of compound with the catalytic pocket of VEGFR-2. Similarly, an MM-GBSA established proper binding showing an exact total binding energy of -36.95 ± 3.03 kcal/Mol. Additionally, the MM-GBSA experiment indicated the vital amino acids in the binding process. Types and number of interactions of compound with catalytic pocket of VEGFR-2 were determined through Protein-Ligand Interaction Profiler (PLIP). As a new compound, the DFT was employed to optimize the molecular structure of compound . The DFT experiments also verified the interaction features of compound with the VEGFR-2 active site. ADMET experiments revealed the general drug-likeness of compound Fascinatingly, the examinations were consistent with the experiments as compound inhibited the VEGFR-2 enzyme with an IC value of 37 nM. Captivatingly, compound inhibited both MCF-7 and HCT 116 cancer cells exhibiting IC values of 10.56 and 7.07 µM exhibiting excellent selectivity indexes of 9.04 and 13.50, respectively.Communicated by Ramaswamy H. Sarma.